Preclinical and clinical aspects of biomodulation of 5-fluorouracil

Cancer Treatment Reviews

Volumn 20, Issue 1, 1994, Pages 11-49

  Sotos, George A ^a   Grogan, Liam ^a   Allegra, Carmen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; IDOXURIDINE; METHOTREXATE; PYRIMIDINE ANTAGONIST; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; SPARFOSIC ACID; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRIMETREXATE; URIDINE; URIDINE DERIVATIVE; ZIDOVUDINE;

COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; METASTASIS; PHOSPHORYLATION; REVIEW;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; BIOLOGICAL RESPONSE MODIFIERS; CISPLATIN; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FLUOROURACIL; HUMAN; IDOXURIDINE; INTERFERONS; LEUCOVORIN; METHOTREXATE; MICE; PHOSPHONOACETIC ACID; RNA, NEOPLASM; URACIL; URIDINE; ZIDOVUDINE;

EID: 0027980010     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(94)90009-4     Document Type: Article

References (166)

1. Biochemical modulation: A modality that has come of therapeutic age
2. Metabolic modulation of fluorouracil by leucovorin: Biochemical rationale and clinical implications
3. Mechanisms of interaction of thymidylate synthetase with 5-fluorouridylate
4. Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism
5. Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate
6. Effect of excess of folates and deoxyinosine on the activity and site of action of 5-fluorouracil
7. The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and a-Tocopherol
8. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells
9. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: Enhancement by leucovorin
10. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines
11. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid
12. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice
13. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice
14. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil
15. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates
16. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft
17. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines
18. Influence of dose of [6 RS] leucovorin in reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts
19. Relationship between dose rate of [6RS] leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts
20. Role of folypolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin
21. 5-fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
22. Lack of interference by the unnatural isomer of 5-for-myltetrahydrofolate with the effects of the natural isomer in leucovorin preparations
23. 5-fluorouracil (5-FU) combined with the [6S]-stereoisomer of folinic acid ([6S]-FA) in high doses for treatment of patients with advanced colorectal carcinoma (CRC)
24. A phase II trial of 5-fluorouracil and L-leucovorin-a multicentre experience
25. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
26. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
27. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
28. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
29. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
30. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
31. Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma
32. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy
33. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
34. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group
35. Folinic acid+5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer
36. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
37. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites
38. Interferon effects upon fluorouracil metabolism by HL-60 cells
39. Interaction of γ interferon and 5-fluorouracil in the H630 human colon carcinoma cell line
40. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects
41. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid
42. Synergistic antitumor effect of fluoropyrimidines and polyinosinic-polycytidylic acid against L1210 leukemia
43. Stimulation of 5-fluorouracil metabolic activation by interferon- α in human colon carcinoma cells
44. Biochemical modulation of fluorouracil with leucovorin and interferon: Preclinical and clinical investigations
45. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma
46. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon α-2a
47. A Phase II study of interferon α-2a (IFN α) in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in advanced colorectal cancer
48. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer
49. Influence of interferon α 2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil
50. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma
51. Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: The Memorial Sloan-Kettering experience
52. Modulation of fluorouracil with recombinant alfa interferon: M. D. Anderson clinical trial
53. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: Preliminary data of a phase II study
54. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon
55. A randomized phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer
56. 5-Fluorouracil (5-FU) plus interferon alfa-2a (Roferon-A) versus 5-fluorouracil plus leucovorin (LV) in metastatic colorectal cancer-results of a multicentre, multinational phase III study
57. Interaction between 5-fluorouracil, [6RS] leucovorin, and recombinant human interferon- α2a in cultured colon adenocarcinoma cells
58. Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer
59. A phase I trial of interferon α-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma
60. Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a
61. Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer
62. Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies
63. cis-Dichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors in mice
64. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
65. The interaction of 5-fluorouracil and cisplatin in human colon carcinoma cells
66. Inhibition by 5-fluorouracil of cis diamminedichloroplatinum(II) -induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line
67. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line
68. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice
69. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer
70. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck
71. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study
72. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
73. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy
74. Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma
75. Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus
76. 5-Fluorouracil enhances azidothymidine cytotoxicity: In vitro, in vivo, and biochemical studies
77. AZT: A biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells
78. Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hematoma and human colon cancer cells
79. Azidothymidine and dipyridamole as biochemical response modifiers: Synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells
80. Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: A phase I study
81. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin
82. Effects of leucovorin on idoxuridine cytotoxicity and DNA incorporation
83. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo
84. Biochemical modulation of 5-bromo-2′-deoxyuridine and 5-iodo-2′-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits
85. Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines
86. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells
87. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer
88. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs
89. Modulation of 5-IODO-2′-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines
90. 125IUdr) by resistant cancer
91. Incorporation of iododeoxyuridine into DNA of granulocytes in patients
92. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver
93. lododeoxyuridine (IDURD) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man: As a radiosensitizer and as a marker for cell kinetic studies
94. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases
95. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine
96. Phase I trial of hepatic artery infusion of 5-iodo-2′-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: Biochemically based combination chemotherapy
97. 5-Fluorouracil (5-FU) pharmacokinetic interactions with iododeoxyuridine (IURD) and bromodeoxyuridine (BURD)
98. Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: A phase I and clinical pharmacological study
99. Phase I study and pharmacokinetics of continuous-infusion 5-fluorouracil (5FU) and 5-IODU-2′-deoxyuridine (IDURD)
100. Leucovorin, fluorouracil, and iododeoxyuridine (LIF): A phase I study in patients with advanced cancer
101. Ode to methotrexate
102. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates
103. Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate
104. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil
105. Time and dose relationships for methotrexate (MTX), fluorouracil (FUra) and combinations of these drugs for maximum cell kill in human CCRF-CEM cells
106. Fluoropyrimidine biochemical modulation in colon cancer: Pharmacology relevant in both the laboratory and the clinic
107. Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy
108. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism
109. Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: Attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate
110. Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines
111. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer
112. Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials
113. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial
114. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells
115. A phase I trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma
116. Biochemistry and clinical activity of N-(Phosphonacetyl)-L-aspartate: A review
117. Modulation of fluorouracil by N-(Phosphonacetyl)-Lasparate: A review
118. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-asparate on cell growth and ribonucleic acid synthesis in human mammary carcinoma
119. Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells
120. Biochemical interactions between N(Phosphonacetyl)-L-aspartate and 5-fluorouracil
121. Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate
122. Therapeutic utility of utilizing low doses of N-(Phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance
123. Overview of N-(Phosphonacetyl)-L-asparate + fluorouracil in clinical trials
124. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(Phosphonacetyl)-L-aspartic acid
125. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(Phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers
126. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer
127. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer
128. A new syndrome: Ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
129. Phase I study of continuous-infusion PALA and 5-FU
130. Phase I study of continuous IV infusion (Cl) 5-FU and leucovorin (LV) plus N-(phosphonacetyl)-L-asparate (PALA) in advanced GI cancer
131. Randomized phase I and clinical pharmacologic trial of pala/5-FU±dipyridamole in patients with advanced cancer
132. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil
133. High-dose 5-fluorouracil with delayed uridine ‘rescue’ in mice
134. Uridine modulation of UTP pool in human tumor cell lines, relevant to uridine rescue of 5-fluorouracil toxicity
135. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue
136. Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools
137. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma
138. In vitro biochemical and in vivo biological studies of the uridine ‘rescue’ of 5-fluorouracil
139. Enhancement by uridine of the anabolism of 5-fluorouracil in mouse T-lymphoma (S-49) cells
140. Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells
141. Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine
142. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase
143. Uridinediphosphoglucose (UDPG) as an alternative to free uridine (UR) for the rescue from 5-fluorouracil (FU)-associated toxicity
144. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine
145. Modulation of fluorouracil toxicity with uridine
146. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity
147. Clinical and pharmacokinetic study of prolonged administration of high-dose uridine intended for rescue from 5-fluorouracil toxicity
148. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine
149. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin
150. Oral uridine (UR) protects from 5-fluorouracil (FU) toxicity in metastatic colorectal carcinoma: Phase I/II trial of phosphonacetyl-L-aspartic acid (PALA) + FU with UR as a rescue agent
151. Uridine (Urd) allows dose-intensification of FAMTX (5-fluorouracil (FU), adriamycin (A), methotrexate (MTX)
152. Pyrimidine acyclonucleosides
153. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase
154. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases
155. Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine
156. Mono- and di-benzyl analogs of acyclouridine (BAU and BBAU) potentiate the antitumor activity of FUdR against the pancreatic DAN, lung LX-1 and colon HCT-8 human carcinoma cell lines
157. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine
158. Benzylacyclouridine-pharmacokinetics, metabolism and biochemical effects in mice
159. Tissue-specific expansion of uridine pools in mice
160. Utility of oral uridine to substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without a uridine phosporylase inhibitor (5-benzylacyclouridine)
161. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine